Velora News

On August 12, 2026, Eli Lilly filed six lawsuits in the United States against companies selling retatrutide. The defendants include Aesthetic Envy, Astra Peptides, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide.
Retatrutide is an investigational peptide being developed by Eli Lilly. It targets three receptors, GLP-1, GIP and glucagon. The compound remains under clinical investigation and has not been approved as a medicine.
What are the lawsuits about?
A key issue is how retatrutide is being sold and marketed. Several sellers offer the compound with statements such as "research use only" or "not for human consumption".
According to Lilly, however, some sellers go beyond supplying the compound strictly for research purposes. Lilly alleges that products carrying these labels are nevertheless being marketed or supplied for human use.
That distinction is central to the cases. Selling a peptide as a research material is legally different from marketing or supplying an unapproved substance for human use.
More than six lawsuits
Lilly's action extends beyond these six companies. The company says it has referred more than 200 individuals and organisations to regulators and law enforcement agencies.
It also says it has reported more than 14,000 websites, advertisements, product listings and social media posts across more than 100 countries.
Lilly is also targeting the infrastructure surrounding these sellers. It has called on social media platforms, e-commerce companies, payment providers and logistics companies to take action against sellers of unapproved retatrutide products.
What does this mean for the peptide market?
The lawsuits are relevant to the wider research peptide market. They show increasing legal attention on experimental peptides, particularly when marketing or product presentation moves towards human use.
The cases may provide further clarity on where US courts draw the line between supplying compounds for legitimate research and marketing or selling unapproved medicines.
Sources: Eli Lilly and Company, Reuters and CBS News. August 2026.

On 23 and 24 July 2026, the FDA's Pharmacy Compounding Advisory Committee, known as PCAC, reviewed seven peptide-related bulk drug substance families for possible inclusion on the Section 503A Bulks List.

The committee issued favourable recommendations for six substance families. BPC-157, KPV and TB-500 each received 8 votes in favour, 6 against and 1 abstention. MOTS-c received 7 votes in favour, 5 against and 2 abstentions. On the second day, Semax received 8 votes in favour, 5 against and 1 abstention, while Epitalon received 7 votes in favour, 4 against and 1 abstention. Emideltide, also known as DSIP, was the only substance family not recommended, with 6 votes in favour, 7 against and 1 abstention.

What was the committee deciding?

The question was whether these bulk drug substances should be recommended for possible inclusion on the 503A Bulks List. Section 503A is a United States framework that can allow a state-licensed pharmacy or physician to prepare a compounded medicine for an identified individual patient, subject to specific legal and quality conditions.

The committee was not deciding whether any of these peptides should become an FDA-approved medicine. It was also not evaluating every claim made about them online. The FDA meeting considered specific nominated uses. These included ulcerative colitis for BPC-157, wound healing and inflammatory conditions for KPV, wound healing for TB-500, obesity and osteoporosis for MOTS-c, neurological indications for Semax, insomnia for Epitalon, and several sleep or neurological indications for emideltide.

Why is this not FDA approval?

FDA approval applies to a defined drug product, formulation, dose, manufacturing process and medical indication. It normally requires a formal application supported by evidence of safety, effectiveness and manufacturing quality. A compounded preparation under Section 503A is exempt from the standard premarket approval requirement when all applicable conditions are met. The FDA does not review each compounded product for safety, effectiveness or quality before it reaches a patient.

A favourable PCAC vote therefore does not prove that a peptide works. It does not establish an approved dose or treatment protocol. It does not approve products sold online, and it does not convert material labelled research use only into a medicine intended for human use.

Why was the vote controversial?

FDA staff briefing documents recommended against adding all seven reviewed substance families. The agency's reviewers highlighted limited or absent human evidence for several nominated uses, incomplete chemical characterisation, uncertainty about dosing and formulation, and insufficiently characterised safety risks, including possible immunogenicity. The advisory committee reached a different policy recommendation for six of the seven families. That disagreement is important context: the positive votes did not remove the underlying evidence gaps.

What happens next?

PCAC recommendations are non-binding. The FDA is not legally required to follow them. A committee vote does not automatically amend the 503A Bulks List. The FDA must still decide how to proceed and, for formal inclusion on the list, normally use notice-and-comment rulemaking before issuing a final regulation. Until an official FDA action changes the applicable list or policy, headlines claiming that the FDA has approved these peptides are inaccurate.

Velora will treat regulatory status, clinical evidence and product quality as separate questions. We will update this article when the FDA publishes a formal decision or changes the 503A Bulks List.

Primary sources consulted:
FDA, Pharmacy Compounding Advisory Committee meeting and briefing materials, 23-24 July 2026.
FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act.
FDA, FD&C Act Provisions that Apply to Human Drug Compounding.

Information about peptides is spread across scientific publications, supplier pages, social media posts and discussion forums. Those sources do not all have the same purpose or the same level of evidence. Important context can easily be lost when a claim is repeated without its original study, limitations or regulatory status.

Velora collects publicly available research context in one place, checks claims against primary sources where possible, and distinguishes clinical evidence, preclinical findings, supplier specifications and calculation models. The goal is not to promise an outcome. It is to make it easier to see what is known, what remains uncertain and where a statement comes from.

We will keep improving each information page as better sources become available. Transparent corrections are part of that process.